Vertex Pharmaceuticals Incorporated (BIT:1VRTX)
Italy · Delayed Price · Currency is EUR | Market Cap | 122.57B +31.7% |
| Revenue (ttm) | 11.41B +10.5% |
| Net Income | 3.50B +8.2% |
| EPS | 13.92 +9.3% |
| Shares Out | n/a |
| PE Ratio | 32.04 |
| Forward PE | 27.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25 |
| Open | 451.00 |
| Previous Close | 454.35 |
| Day's Range | 445.90 - 451.00 |
| 52-Week Range | 342.00 - 480.25 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
News
Vertex to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor...
Vertex Pharmaceuticals Thrives on Higher Sales and Guidance
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 43 outlier institutional inflow signals and gained over 1,738%.
Vertex Pharmaceuticals Thrives on Higher Sales and Guidance
VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.
Vertex Pharmaceuticals price target raised to $626 from $617 at Barclays
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $626 from $617 and keeps an Overweight rating on the shares following the Q3 report.
Vertex Pharmaceuticals price target raised to $660 from $558 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $660 from $558 and keeps an Outperform rating on the shares. The company reported “strong” Q3 results, with sales…
Vertex Pharmaceuticals price target raised to $620 from $600 at BMO Capital
BMO Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $620 from $600 and keeps an Outperform rating on the shares. The management noted confidence in a regulatory…
Vertex Pharmaceuticals price target raised to $575 from $550 at TD Cowen
TD Cowen raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $575 from $550 and keeps a Buy rating on the shares. The firm said they posted solid Q3…
Vertex Pharmaceuticals price target raised to $640 from $615 at UBS
UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $640 from $615 and keeps a Buy rating on the shares.
Vertex Pharmaceuticals price target raised to $600 from $576 at RBC Capital
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $600 from $576 and keeps an Outperform rating on the shares after its Q3 results. Solid cash flow…
Vertex Pharmaceuticals price target raised to $619 from $595 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $619 from $595 and keeps an Overweight rating on the shares. Vertex reinforced confidence in povetacicept ahead of…
Vertex Pharmaceuticals price target raised to $563 from $500 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $563 from $500 and keeps a Hold rating on the shares.
Vertex Pharmaceuticals price target lowered to $660 from $665 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $660 from $665 and keeps an Overweight rating on the shares after “generally in line”…
Vertex Pharmaceuticals price target raised to $650 from $550 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $650 from $550 and keeps an Overweight rating on the shares. The firm says management…
Vertex Pharmaceuticals price target raised to $725 from $654 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $725 from $654 and keeps a Buy rating on the shares. Vertex delivered in-line Q3 revenue and raised…
Vertex Pharmaceuticals price target raised to $570 from $560 at JPMorgan
JPMorgan raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $570 from $560 and keeps an Overweight rating on the shares. The firm views the company’s Q3 results as…
Vertex Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue grew 12% YoY, supported by CF and newer launches. FY2026 revenue guidance rose to $13.15B-$13.25B, while the Crinetics integration adds rare endocrinology and expanded pipeline programs.
Vertex Pharmaceuticals Earnings release: Q3 2026
Vertex Pharmaceuticals released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Vertex Pharmaceuticals Slides: Q3 2026
Vertex Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Vertex Pharmaceuticals Quarterly report: Q3 2026
Vertex Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 2, 2026.
Vertex Pharmaceuticals reports Q3 adjusted EPS $4.76, consensus $4.78
Reports Q3 revenue $3.44B, consensus $3.43B. “Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of t...
Vertex Reports Third Quarter 2026 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 ...
Vertex Pharmaceuticals Transcript: American Society of Nephrology (ASN) Kidney Week 2026
AMPLITUDE is fully enrolled, with interim results expected early next year and FDA discussions anchored to one-year eGFR. Povetacicept showed a 52% week-36 proteinuria reduction in IgAN; coverage announcements are expected in H1 2027.
Vertex Pharmaceuticals Slides: FY 2026
Vertex Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 23, 2026.
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), p...
